San Diego Life Sciences Roundup: Santarus, Shire, Illumina, & More

Xconomy San Diego — 

An appellate court ruling could spell relief for the heartburn that Santarus has been feeling over the past couple of years. We have the latest developments, along with the rest of San Diego’s life sciences news.

—San Diego-based Santarus (NASDAQ: SNTS) said it partially won a federal appeals court ruling regarding patents Santarus had asserted for omeprazole sodium bicarbonate (Zegrid). Santarus CEO Gerald Proehl welcomed the ruling, which sent the case back to the trial court. Santarus cut more than a third of its workforce two years ago after a competitor started selling a cheaper generic version of the drug, which is used to treat chronic heartburn.

Shire (NASDAQ: SHPG), the Irish drug giant, said the lead product of its new San Diego-based regenerative medicine division (previously known as Advanced BioHealing) has made its first move in a global commercialization strategy. The company said Canadian regulators have approved Dermagraft, a skin graft derived from human fibroblasts, for the treatment of diabetic foot ulcers. In June, Shire unveiled plans to build a campus in San Diego for the business known as Shire RM.

—San Diego-based Histogen, a regenerative medicine startup, said the U.S. Patent & Trademark Office has issued the company’s first patent. The patent covers Histogen’s method of growing cells under low oxygen and suspension conditions to produce naturally secreted proteins. It represents a milestone for Histogen, which is … Next Page »

Single PageCurrently on Page: 1 2